Immune determinants of the association between tumor mutational burden and immunotherapy response...
The FDA has recently approved high tumor mutational burden (TMB), defined by ≥10 mutations/Mb, as a biomarker for the treatment of solid tumors with pembrolizumab, an immune checkpoint inhibitor...
biorxiv.org